Top 10 Biotech Solution Companies in Europe - 2021

Technology has always been at the heart of biotech. The emergence of advanced computing technology such as machine learning and artificial intelligence enables companies to expand the scope and scale of their research and improve efficiency in the manufacturing process. In addition, the evolution of cloud computing technology has removed a barrier for many innovations in biotech. The ability to run applications through the cloud allows companies to store and analyze data without having to invest in expensive computer hardware.

Today, clinical trials have been heavily digitized enabling biotech companies to test treatments on more patients in less time. Machine learning technology also holds promise for enabling biotech companies to quickly analyze data from current trials to predict the effectiveness of treatments down to the molecular level. They can also revisit data from previous trials to see if anything may have been missed, or if there may be new or different uses for an existing drug. For agricultural applications, gene editing can produce varieties of crops that are more resistant and produce higher yields. The development of biological pesticides has the potential to protect crops without the use of harmful chemicals or environmental damage.

At this juncture, there is a wide variety of solution providers entering the industry with a set of advanced biotech offerings. To help companies navigate through the best-of-breed biotech solution providers, CIO Review has compiled a list of ’10 Most Promising Biotech Solution Providers in Europe - 2021.’ Besides, the magazine also comprises insights from thought leaders in the sector on the industry trends, best practices, recent innovations, and their advice for aspiring CIOs.

We present to you CIO Review’s “10 Most Promising Biotech Solution Providers in Europe - 2021.”

Top Biotech Solution Companies in Europe

AMYRA Biotech AG is a Swiss based, privately held biotech company that develops a highly promising, novel, enzyme-based treatment for celiac disease (gluten intolerance) with high probability of clinical, regulatory and commercial success.AMYRA’s proprietary and patented enzymes—the only know exopeptidases to completely degrade GIPs—cleave GIPs at different motifs and rapidly converts them into harmless single amino acids and dipeptides that are inert and resorbed in the body, without activating the immune system

A unique start-up company, PEACCEL “The AI company for Life Sciences” offers an innovative unique and versatile AI-platform named innov’SAR that allows predicting multiple types of innovation in Life Sciences and biotechnology and provides solutions to make risky and investment intensive drug and enzyme development more efficient. PEACCEL successfully bridges the gap between AI and the Life Sciences sector through its stellar "platform technology" that combines the benefits of various other technologies to solve the Life Sciences market's diverse impediments

Alexion

Alexion

The company has delivered transformative medicines for people with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD), generalized Myasthenia Gravis (gMG), hypophosphatasia (HPP), and lysosomal acid lipase deficiency (LAL-D)

argenx

argenx

Brings antibody engineering expertise to pioneering researchers with the intent to advance immunology breakthroughs into differentiated medicines for patients

HistoGeneX

HistoGeneX

HistoGeneX Laboratories is a privately held service provider of biomarker technologies for translational and clinical research and is a CAP, CLIA and BELAC-accredited laboratory. With facilities located in Antwerp, Belgium and Chicago, Illinois, and Jining, China, HistoGeneX provides a networked footprint for global clinical trials.Our services and products stem from a pathology and patient care perspective. We are experts at handling all human biological specimens and deploy the relevant technologies to extract the valuable information contained within for research and diagnostic applications

Jazz Pharmaceuticals [NASDAQ: JAZZ]

Jazz Pharmaceuticals [NASDAQ: JAZZ]

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients. We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.

Kiadis

Kiadis

Kiadis Pharma is focused on cell-based immunotherapy products for the treatment of life threatening diseases. Kiadis is focused on developing new cancer immunotherapeutics as well as novel adjunctive treatments for patients undergoing hematopoietic stem cell transplants

PDC*line Pharma

PDC*line Pharma

Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) pre-loaded with peptides that are derived from target tumor antigens. Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in clinical development (PDC*lung) and on neoantigens (PDC*Neo)

Regeneron

Regeneron

Discovers, invents, and develops biopharmaceutical medicines

Vertex

Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases